News Release
View printer-friendly version
|
<< Back |
ZUG,
Title:
Presenter:
Time and Date:
Location: Hilton Chicago, Continental C
Title: Induction of HbF to Treat β-hemoglobinopathies – Bringing CRISPR to the Clinic
Presenter:
Time and Date: Friday, May 18,
Location: Hilton Chicago, International Ballroom North
Title: Allogeneic CAR T Cells with Multiple Therapeutically Favorable Edits Can Be Created Efficiently Using CRISPR/Cas9
Presenter:
Time and Date:
Location: Hilton Chicago, P792, Stevens Salon C, D
Title: Efficient Clinical Scale CRISPR/Cas9-Mediated Editing of Plerixafor-Mobilized Hematopoietic Stem and Progenitor CD34+ Cells for Treatment of Sickle Cell Disease
Presenter:
Time and Date:
Location: Hilton Chicago, Salon A-3,4
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge,
CONTACTS
MEDIA CONTACT:
WCG on behalf of CRISPR
+1 347-658-8290 jpaganelli@wcgworld.com
INVESTOR CONTACT:
+1 617-307-7227 chris.erdman@crisprtx.com
+1 339-970-2843 chris.brinzey@westwicke.com
Source: CRISPR Therapeutics AG